Table 4.

Results of univariate and multivariate analysis.

Characteristic	Patients (N)	Median OS (months)	Univariate P value	Multivariate P value	Median LRPFS (months)	Univariate P value	Multivariate P value	Median PFS (months)	Univariate P value	Multivariate P value
Age group
<70 years	586	25.8	0.33	—	16.3	0.26	—	12.8	0.19	—
≥70 years	60	22.5			14.1			10.9
Gender
Male	400	24.1	0.51	—	14.4	0.62	—	10.9	O.48	—
Female	246	25.5			15.9			12.6
KPS
90–100	461	27.9	0.002	0.004	17.6	0.001	0.001	12.8	0.0011	0.024
70–80	185	22.6			13.9			10.7
Histology
AC	348	24.4	0.84	—	14.7	0.75	—	12.2	0.39	—
SCC	298	25.3			15.9			11.0
T-stage
1-2	289	39.3	<0.001	<0.001	17.3	<0.001	<0.001	12.8	<0.001	<0.001
3-4	357	22.2			13.1			10.6
N-stage
2	325	30.4	<0.001	<0.001	19.3	<0.001	<0.001	14.7	<0.001	<0.001
3	321	19.9			11.0			8.3
Stage
IIIB	385	33.4	<0.001	<0.001	19.1	<0.001	<0.001	15.4	<0.001	<0.001
IIIC	261	20.2			10.8			7.9
Chemotherapy cycles
2-3	529	26.8	<0.001	<0.001	17.3	<0.001	<0.001	12.8	<0.001	<0.001
1	117	20.2			11.4			9.3
RT group
ENI	323	25.2	0.69	—	15.3	0.49	—	11.7	0.57	—
IFRT	323	24.6			15.1			11.2

OS: overall survival; LRPFS: locoregional progression-free survival; PFS: progression-free survival; KPS: Karnofsky performance score; SCC: squamous cell cancer; AC: adenocarcinoma; T: tumor; N: node; RT: radiotherapy; ENI: elective nodal irradiation; IFRT: involved-field radiotherapy.